Back to search
Refractory or Recurrent Hypermutated Malignancies
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Refractory or Recurrent Hypermutated Malignancies trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Refractory or Recurrent Hypermutated Malignancies trials you may qualify forThis phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (br…
This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric patients with recurrent or refractory hypermutant malignancies aged 12 mo…